Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
ImmusanT
Biotech
ImmusanT cans phase 2 celiac trial after interim efficacy review
The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.
Nick Paul Taylor
Jun 26, 2019 8:52am
ImmusanT to move into Type 1 diabetes with JDRF backing
Sep 11, 2018 8:00am
Chutes and Ladders—Lilly's oncology chief announces retirement
May 25, 2018 9:29am
ImmusanT goes on hiring spree ahead of celiac vaccine trial
May 21, 2018 11:22am
ImmusanT's celiac disease immunotherapy passes first clinical test
Feb 22, 2017 9:27am
